Pharmacy benefit manager shares dropped sharply Wednesday as lawmakers introduced bipartisan legislation requiring health insurers and PBMs to divest pharmacy operations within three years. The proposal intensifies scrutiny of the PBM industry's influence over drug pricing.
Bipartisan Bill Targets Vertical Integration in Healthcare
According to Reuters, following the presentation of a bipartisan measure on Wednesday, which would compel health insurers or drug intermediaries to sell off their pharmacy businesses, shares of companies owning pharmacy benefit managers declined.
The majority of pharmacy benefit management (PBM) in the US is controlled by CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum. All three of these parent firms also own health insurance businesses.
Following the initial reporting of the bill in the Wall Street Journal, all three firms' shares fell by 4.8% to 5.5%.
The bill, which is being co-sponsored by Republican Josh Hawley and Democratic Elizabeth Warren in the United States Senate, would require, within three years, that companies that own health insurers or pharmacy benefit managers sell their shares in pharmacies.
Healthcare Stocks React to Bipartisan Proposal
This bill will be submitted in Congress with the support of Republican Diana Harshbarger and Democratic Jake Auchincloss.
Pharmacy benefit managers (PBMs) mediate pricing negotiations for prescription prescriptions between insurance companies, pharmacies, and pharmaceutical companies. PBMs then pay pharmacies directly for the medications covered by their contracts.
They have already been investigated for the impact they have on the cost of prescription drugs.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business. My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen," Senator Warren stated.
Other Insurers Feel the Ripple Effect of PBM Legislation
Other insurance companies' stock prices dropped 1% to 3%. This included Centene, Elevance, and Humana, Investing.com shares.
"The latest introduction of potential legislation to restrict PBM operations and broader healthcare vertical integration is unlikely to gain traction, although it is hard to dismiss outright," Michael Cherny, an analyst at Leerink Partners, said.
Insurance company stock has taken a beating following last week's shooting death of UnitedHealth health insurance unit CEO Brian Thompson outside a Manhattan hotel.


Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026
Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns
U.S. Stocks Slip as Gold Rebounds Ahead of Year-End, Markets Eye 2026 Outlook
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading
Singapore GDP Growth Surges in 2025 but Outlook Remains Cautious Amid Global Trade Risks
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 



